Coumadin Related Published Studies
Well-designed clinical trials related to Coumadin (Warfarin)
Thrice weekly warfarin administration in haemodialysis patients. [2009.10]
Dabigatran versus warfarin in patients with atrial fibrillation. [2009.09.17]
Use of Warfarin in People with Low Glomerular Filtration Rate or on Dialysis. [2009.09.09]
Practical application of the 10-mg warfarin initiation nomogram. [2009.09]
Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. [2009.08.15]
Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system. [2009.08]
The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial. [2009.07]
A 10 mg warfarin initiation nomogram is safe and effective in outpatients starting oral anticoagulant therapy for venous thromboembolism. [2009.07]
Effects of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin. [2009.05.01]
Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin. [2009.05]
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. [2009.05]
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. [2009.03.31]
Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. [2009.03.03]
Prevention of venous thrombosis by warfarin after permanent transvenous leads implantation in high-risk patients. [2009.03]
Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. [2009.03]
Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. [2009.02.14]
Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. [2009.01.27]
A 10 mg warfarin initiation nomogram is safe and effective in outpatients starting oral anticoagulant therapy for venous thromboembolism. [2009.01.18]
Bridge or continue Coumadin for device surgery: a randomized controlled trial rationale and design. [2009.01]
Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. [2008.12.01]
Warfarin prevents venous obstruction after cardiac devices implantation in high-risk patients: partial analysis. [2008.12]
Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. [2008.10]
Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. [2008.08]
Interaction between warfarin and Panax ginseng in ischemic stroke patients. [2008.07]
Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? [2008.06]
The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. [2008.06]
Pharmacodynamics of Uniform versus Nonuniform Warfarin Dosages. [2008.06]
Effect of ximelagatran and warfarin on stroke subtypes in atrial fibrillation. [2008.05]
CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. [2008.03]
Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer. [2008.03]
Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. [2008]
Less benefit from warfarin in diabetics after myocardial infarction? [2008]
The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon. [2008]
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. [2007.11.27]
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). [2007.11.01]
Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study. [2007.11]
Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics. [2007.10]
Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. [2007.09]
Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. [2007.08.15]
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. [2007.08.11]
Warfarin cessation before cardiopulmonary bypass: lessons learned from a randomized controlled trial of oral vitamin K. [2007.07]
A cautionary note on data sources for evidence-based clinical decisions: warfarin and stroke prevention. [2007.07]
low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP). [2007.07]
Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4. [2007.06]
The Effect of Acetaminophen on the International Normalized Ratio in Patients Stabilized on Warfarin Therapy. [2007.05]
Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. [2007.05]
Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. [2007.03.15]
Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. [2007.01]
Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin. [2007]
Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study. [2006.12]
Cranberry does not affect prothrombin time in male subjects on warfarin. [2006.12]
Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. [2006.11]
Warfarin vs aspirin for symptomatic intracranial stenosis: subgroup analyses from WASID. [2006.10.10]
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. [2006.10]
Study on warfarin plasma concentration and its correlation with international normalized ratio. [2006.09.18]
Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies--a randomized, controlled study. [2006.09]
Comparison of a single end point to determine optimal initial warfarin dosing (5 mg versus 10 mg) for venous thromboembolism. [2006.08.15]
Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects. [2006.08]
Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial. [2006.07]
Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin. [2006.06]
Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin. [2006.06]
Reducing warfarin medication interactions: an interrupted time series evaluation. [2006.05.08]
Moderate alcohol consumption and safety of lovastatin and warfarin among men: the post-coronary artery bypass graft trial. [2006.05]
Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. [2006.04.24]
Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. [2006.04]
Aged garlic extract may be safe for patients on warfarin therapy. [2006.03]
Effectiveness of manual pressure hemostasis following transfemoral coronary angiography in patients on therapeutic warfarin anticoagulation. [2006.02.15]
Comparison of the efficacy and safety profiles of intravenous vitamin k and fresh frozen plasma as treatment of warfarin-related over-anticoagulation in patients with mechanical heart valves. [2006.02.01]
Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. [2006.02]
Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study. [2006]
Warfarin therapy and systolic hypertension in men with atrial fibrillation. [2005.12]
Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. [2005.10]
Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects. [2005.10]
A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. [2005.08]
Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. [2005.08]
Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium. [2005.08]
Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. [2005.07]
Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials. [2005.07]
Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. [2005.06.20]
Efficacy of computer-aided dosing of warfarin among patients in a rehabilitation hospital. [2005.06]
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). [2005.05]
Influence of warfarin on symptoms of fatigue: findings of a randomized trial. [2005.05]
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. [2005.04]
Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. [2005.04]
No effect of encapsulation on the pharmacokinetics of warfarin. [2005.04]
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. [2005.03.31]
Efficacy and tolerability of the switch from a branded to a generic warfarin sodium product: an observer-blinded, randomized, crossover study. [2005.03]
Paracetamol: a haemorrhagic risk factor in patients on warfarin. [2005.03]
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. [2005.02.09]
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. [2005.02.09]
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. [2005.01.15]
Hemorrhagic complications during long-term postoperative warfarin administration in patients undergoing lower extremity arterial bypass surgery. [2004.11]
Low-intensity warfarin reduces thrombin generation and fibrin turnover, but not low-grade inflammation, in men at risk of myocardial infarction. [2004.11]
Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. [2004.10]
The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. [2004.08]
Improving the outcomes of anticoagulation: an evaluation of home follow-up of warfarin initiation. [2004.08]
Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled Trial. [2004.07.06]
The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. [2004.07]
Effect of aspirin and warfarin therapy in stroke patients with valvular strands. [2004.06]
Increased levels of soluble tissue factor during long-term treatment with warfarin in patients after an acute myocardial infarction. [2004.05]
Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. [2004.05]
|
